Drugs / Expanded CB-NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05040568 | Feb 2022 → Jan 2026 | colon carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Expanded CB-NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05040568 ↗ |
| Modality | Cell therapy | “expanded CB-NK cells” NCT05040568 ↗ |
| Route | Intravenous | “Given IV” NCT05040568 ↗ |